Sands Capital

HAWK:AI GmbH is a fintech company based in Munich, Germany, founded in 2018. The company specializes in providing a money laundering detection and investigation platform that leverages machine-learning techniques to assist financial institutions in combating financial crime. HAWK:AI supports the end-to-end financial crime compliance process, encompassing transaction monitoring, investigation, filing, and maintaining audit trails. By focusing on effective information sharing, the platform enhances the capabilities of anti-money laundering and fraud surveillance teams within banks, payment companies, and fintech organizations, ultimately improving their efficiency and effectiveness in addressing financial corruption.

Flock Safety is a company that specializes in security solutions through the use of automated license plate recognition (ALPR) cameras. Its primary product, the ALPR camera system, is designed for use by neighborhoods, law enforcement agencies, and businesses to capture and analyze vehicle license plates. This technology aids in both preventing and solving crimes by providing actionable data to local authorities. Flock Safety's platform emphasizes community collaboration, integrating efforts from cities, businesses, schools, and law enforcement to enhance public safety. The company's full-service, maintenance-free technology is trusted by various communities as a means to deter crime and promote a safer environment for residents. Additionally, the system proactively alerts police when stolen vehicles enter monitored areas, enabling faster response and community involvement in crime prevention.

PgEdge specializes in providing distributed PostgreSQL solutions that enhance network edge performance, minimize data latency, and ensure ultra-high availability for critical applications. The company's technology features multi-master replication capabilities, allowing for active-active operations across various geographic regions. This setup enables developers to easily build and deploy highly distributed database applications within a fully managed cloud service. By integrating multi-active, multi-master, multi-region, and multi-cloud functionalities, PgEdge supports users in creating robust database environments that can efficiently operate on a global scale.

CompScience is a technology company that specializes in AI-driven solutions for workers' compensation insurance, emphasizing workplace safety through data analysis and risk identification. The platform aids organizations in evaluating their safety protocols, pinpointing potential hazards, and implementing effective risk management strategies. By utilizing machine learning algorithms, CompScience analyzes historical data to forecast future incidents and suggest preventive measures, ultimately helping businesses lower claims costs and enhance employee safety. Furthermore, the platform fosters communication between safety teams and management, ensuring that safety initiatives align with organizational objectives. It also serves logistics and manufacturing sectors by providing actionable insights, safety monitoring, and a user-friendly dashboard, contributing to measurable reductions in injuries and workers' compensation costs while improving overall performance and employee satisfaction.

Dreadnode is an offensive machine learning platform that specializes in research, evaluations, and cyber ranges aimed at enhancing cybersecurity. The company focuses on conducting offensive engagements against AI systems, providing essential services such as developing assessment methodologies and tools. Through its offerings, Dreadnode enables users to effectively manage and mitigate risks associated with their systems, ensuring a safer operational environment.

Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.

Databricks Inc. is a technology company that provides a unified data analytics cloud platform designed to facilitate data engineering and collaborative data science. The company offers a comprehensive suite of tools, including a just-in-time data platform that simplifies data integration, real-time experimentation, and deployment of production applications for developers and data scientists. Key products include Databricks Delta, which combines the capabilities of data warehouses with low-latency streaming, MLflow for managing the machine learning lifecycle, and Delta Lake for handling batch and streaming data. Databricks serves a diverse range of industries, including advertising, healthcare, manufacturing, and telecommunications, and has established strategic partnerships with various organizations to enhance its offerings. Founded in 2013, Databricks is headquartered in San Francisco, California, with additional offices in London, Amsterdam, and Bengaluru.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Vitara Biomedical develops a therapeutic platform to support premature infants. It offers natural physiological processes and hopes to transform neonatal care for newborns and their families into a lifetime of possibilities.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Blue Earth Therapeutics is a radiopharmaceutical company that specializes in the advancement of next-generation targeted radiotherapeutics to treat cancer patients. It is a sister company of Blue Earth Diagnostics.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

Inhibikase Therapeutics has developed the first small molecule platform capable of treating both bacterial and viral infectious diseases through a common mechanism of action in the host. The company's host targeting strategy creates multi-pathogen anti-infectives without stimulating resistance.

PgEdge specializes in providing distributed PostgreSQL solutions that enhance network edge performance, minimize data latency, and ensure ultra-high availability for critical applications. The company's technology features multi-master replication capabilities, allowing for active-active operations across various geographic regions. This setup enables developers to easily build and deploy highly distributed database applications within a fully managed cloud service. By integrating multi-active, multi-master, multi-region, and multi-cloud functionalities, PgEdge supports users in creating robust database environments that can efficiently operate on a global scale.

Anduril Industries, Inc. is a defense technology company that designs, manufactures, and deploys advanced hardware and software products to address complex national security challenges faced by the United States and its allies. Founded in 2017 and headquartered in Irvine, California, with additional offices in Washington, D.C., and Seattle, the company employs top technical talent to create innovative solutions. Its offerings include the Lattice Platform, which integrates artificial intelligence, computer vision, and machine learning to provide a cohesive operational picture; the Sentry Tower, which collects data across the electromagnetic spectrum; and the Ghost sUAS, a man-portable unmanned aerial system capable of performing various missions autonomously. Additionally, Anduril develops the Anvil sUAS, designed for precise drone threat interception while providing visual feedback for human operators. Through its cutting-edge technology, Anduril aims to enhance defense capabilities and support frontline personnel in safeguarding national interests.

Credo AI is focused on enabling enterprises to responsibly develop, adopt, and utilize artificial intelligence at scale. The company offers an AI governance platform that automates oversight and risk management, ensuring compliance with emerging global standards such as the EU AI Act and NIST. Founded in 2020, Credo AI's platform supports organizations in measuring, monitoring, and managing risks associated with AI, which helps build customer trust and unlock sales opportunities. By prioritizing human control over AI technologies, Credo AI aims to enhance both business outcomes and societal benefits. The company has received recognition in the industry, including listings in CBInsights AI 100 and accolades from the World Economic Forum and Fast Company.

PolyAI Ltd is a company that specializes in developing a conversational artificial intelligence platform aimed at enhancing human-machine voice interactions. Founded in 2017 and headquartered in London, United Kingdom, with an additional office in New York, the company focuses on creating enterprise voice assistants capable of engaging in natural conversations with customers. These assistants utilize advanced machine learning and natural language processing to understand and respond to customer inquiries, regardless of phrasing or dialect. The platform supports features such as multilingual capabilities, data acquisition, and dynamic flow design, facilitating the creation of human-like interactions and improving customer service experiences across various industries.

Ramp Holdings, Inc. specializes in Software-as-a-Service solutions aimed at modernizing financial operations and enhancing content delivery. The company provides a comprehensive platform that includes tools for corporate card management, expense tracking, bill payments, and accounting integrations. By leveraging advanced technologies such as speech-to-text, natural language processing, and search engine optimization, Ramp allows organizations to maximize the value of their video content and drive increased engagement. Its offerings also include various video management solutions, notably for the SharePoint ecosystem, which facilitate seamless integration, live streaming, and efficient content delivery. Founded in 1948 and based in Boston, Massachusetts, Ramp operates as a subsidiary of Raytheon BBN Technologies Corporation. The company serves diverse industries, including media, finance, healthcare, and technology, with a focus on creating cost-effective and insightful financial tools for organizations.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

HealthSnap, Inc. is a healthcare technology company that specializes in developing solutions for processing patient lifestyle data to enhance healthcare delivery. Incorporated in 2015 and headquartered in Miami, Florida, with an additional office in San Mateo, California, HealthSnap offers a comprehensive Virtual Care Management Platform. This platform integrates various services, including Remote Patient Monitoring (RPM) and Chronic Care Management (CCM), to assist healthcare organizations in improving patient outcomes, reducing healthcare utilization, and diversifying revenue streams. By utilizing data from wearables, remote sensors, and patient questionnaires, HealthSnap's platform enables effective care coordination and automated management of chronic conditions, empowering clinicians with the necessary tools to prevent and manage lifestyle-related diseases efficiently.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.

LimaCharlie is a provider of Security Infrastructure as a Service (SIaaS), offering a platform that simplifies information security management for businesses. By delivering tools and services on-demand, LimaCharlie enables organizations to efficiently manage their security operations, akin to major cloud providers. The platform includes endpoint-driven security tools, telemetry storage, and a comprehensive incident response pipeline, allowing users to create customized detection and response rules. Additionally, LimaCharlie supports the development of Managed Security Service Providers (MSSPs) and Security Operations Centers (SOCs) by offering a variety of pre-made services and APIs, empowering users to build and monetize their own security products.

Elephas is a live tumor imaging diagnostics company focused on enhancing cancer treatment through personalized therapy determination. The company leverages advancements in cancer biology, multimodal microscopy, engineering, and artificial intelligence to analyze human live tumor fragments. This innovative platform aims to improve clinical decision-making for oncologists, enabling them to tailor treatments to individual patients. Additionally, Elephas seeks to accelerate drug development processes, addressing the urgent need for effective cancer therapies in a rapidly evolving healthcare landscape.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

SafeRide Health is a healthcare technology platform that focuses on enhancing medical transportation and care coordination for vulnerable populations. The company provides a comprehensive platform that empowers health plans to manage their members effectively, ensuring greater intelligence and control over services. By utilizing advanced technology and artificial intelligence, SafeRide Health facilitates end-to-end data transparency, which in turn improves patient experiences and outcomes. The platform aims to transform the patient journey, enhance population health, and reduce overall healthcare costs through its innovative solutions, including patented fleet management capabilities tailored to the healthcare industry.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Ramp Holdings, Inc. specializes in Software-as-a-Service solutions aimed at modernizing financial operations and enhancing content delivery. The company provides a comprehensive platform that includes tools for corporate card management, expense tracking, bill payments, and accounting integrations. By leveraging advanced technologies such as speech-to-text, natural language processing, and search engine optimization, Ramp allows organizations to maximize the value of their video content and drive increased engagement. Its offerings also include various video management solutions, notably for the SharePoint ecosystem, which facilitate seamless integration, live streaming, and efficient content delivery. Founded in 1948 and based in Boston, Massachusetts, Ramp operates as a subsidiary of Raytheon BBN Technologies Corporation. The company serves diverse industries, including media, finance, healthcare, and technology, with a focus on creating cost-effective and insightful financial tools for organizations.

OneTrust, LLC is a technology company that specializes in privacy management and compliance solutions. Founded in 2016 and headquartered in Atlanta, Georgia, the company offers a comprehensive platform that automates various aspects of privacy program management, including privacy impact assessments, data inventory mapping, and risk remediation actions. OneTrust’s solutions facilitate compliance with global regulations by providing tools for vendor risk management, incident reporting, and website compliance, as well as managing data subject rights and consent. The platform serves a diverse clientele ranging from multinational corporations to small and medium enterprises, allowing them to collaborate effectively on privacy risks associated with customer, employee, and vendor data. OneTrust also provides training and certification programs, ensuring that organizations can maintain continuous compliance through ongoing audits and assessments. With additional offices worldwide, OneTrust is positioned to support businesses in navigating the complexities of privacy regulations across various sectors and jurisdictions.

Luminoah is a medical device company focused on enhancing chronic disease care through its innovative enteral nutrition platform. The company has developed a wearable system that integrates durable medical equipment with consumable nutrition pouches. This platform allows for personalized enteral feeding, enabling doctors to remotely monitor patients and track feeding status online. By combining technology and nutrition, Luminoah aims to revolutionize the enteral feeding market and improve clinical outcomes for individuals requiring nutritional support.

Hungry is a Washington D.C.-based company that operates a food catering and delivery marketplace. Founded by Eman Pahlavani, Shy Pahlevani, and Jeff Grass, Hungry connects independent chefs with businesses seeking high-quality catered meals. The platform offers a variety of prepared meals for different occasions, allowing businesses to order office lunches from a network of local chefs with curated menus. Hungry is committed to community improvement through initiatives like the ‘Fight Against Hunger’ program, which donates one meal to those in need for every two purchased, and the ‘WeRecycle’ program, which promotes environmental waste reduction by offering biodegradable plates and cutlery. The company has operations in several major U.S. cities, including Philadelphia, Atlanta, Boston, and New York City, with plans to expand its footprint to 23 cities by the end of 2021.

PgEdge specializes in providing distributed PostgreSQL solutions that enhance network edge performance, minimize data latency, and ensure ultra-high availability for critical applications. The company's technology features multi-master replication capabilities, allowing for active-active operations across various geographic regions. This setup enables developers to easily build and deploy highly distributed database applications within a fully managed cloud service. By integrating multi-active, multi-master, multi-region, and multi-cloud functionalities, PgEdge supports users in creating robust database environments that can efficiently operate on a global scale.

HAWK:AI GmbH is a fintech company based in Munich, Germany, founded in 2018. The company specializes in providing a money laundering detection and investigation platform that leverages machine-learning techniques to assist financial institutions in combating financial crime. HAWK:AI supports the end-to-end financial crime compliance process, encompassing transaction monitoring, investigation, filing, and maintaining audit trails. By focusing on effective information sharing, the platform enhances the capabilities of anti-money laundering and fraud surveillance teams within banks, payment companies, and fintech organizations, ultimately improving their efficiency and effectiveness in addressing financial corruption.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

Tellius, Inc. is an AI-powered business analytics platform established in 2015 and headquartered in Reston, Virginia. The platform is designed to help enterprises accelerate data-driven insights and decision-making by integrating artificial intelligence with a search-enabled interface for ad hoc exploration. Unlike traditional business intelligence tools, Tellius employs a distributed architecture that leverages Apache Spark, enabling it to handle big data efficiently. The platform automates the interpretation and analysis of data through machine learning, identifying hidden correlations, trends, and anomalies. Users can pose questions about their business data and receive immediate insights, which are presented as suggested visualizations and predictive models, facilitating a more comprehensive understanding of their operations.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Vitara Biomedical develops a therapeutic platform to support premature infants. It offers natural physiological processes and hopes to transform neonatal care for newborns and their families into a lifetime of possibilities.

Elephas is a live tumor imaging diagnostics company focused on enhancing cancer treatment through personalized therapy determination. The company leverages advancements in cancer biology, multimodal microscopy, engineering, and artificial intelligence to analyze human live tumor fragments. This innovative platform aims to improve clinical decision-making for oncologists, enabling them to tailor treatments to individual patients. Additionally, Elephas seeks to accelerate drug development processes, addressing the urgent need for effective cancer therapies in a rapidly evolving healthcare landscape.

Cleerly is a healthcare company focused on improving the prevention of heart attacks through innovative digital care pathways. It aims to establish a new standard for coronary artery disease by combining advanced clinical science with cutting-edge artificial intelligence. Cleerly's platform offers a non-invasive approach that quantifies and characterizes plaque buildup in coronary arteries, enhancing the understanding of cardiovascular health. By providing actionable clinical insights, the company enables healthcare providers to better identify at-risk patients and implement early treatment strategies. Ultimately, Cleerly's data-driven solutions aspire to deliver significant value to the healthcare system while improving heart health outcomes for individuals susceptible to heart attacks.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.

Papercup is a London-based company that specializes in automating the dubbing and translation of video content using advanced artificial intelligence. Its software employs a combination of Bayesian neural networks and speech synthesis to create synthetic voice-overs that closely resemble human speech. This technology allows video creators to produce content in their original language while enabling users to translate videos into their preferred languages. Papercup's platform streamlines the localization process, making it faster and more cost-effective compared to traditional methods. The company also incorporates a quality assurance system where professional translators review the voiceovers, ensuring high accuracy and broadcast-quality results. By enhancing video accessibility, Papercup aims to help content owners engage with a global audience more effectively.

LimaCharlie is a provider of Security Infrastructure as a Service (SIaaS), offering a platform that simplifies information security management for businesses. By delivering tools and services on-demand, LimaCharlie enables organizations to efficiently manage their security operations, akin to major cloud providers. The platform includes endpoint-driven security tools, telemetry storage, and a comprehensive incident response pipeline, allowing users to create customized detection and response rules. Additionally, LimaCharlie supports the development of Managed Security Service Providers (MSSPs) and Security Operations Centers (SOCs) by offering a variety of pre-made services and APIs, empowering users to build and monetize their own security products.

Redbud Brands is a brand development studio focused on creating disruptive companies in the consumer space, particularly within the premium consumer packaged goods sector. The firm partners with visionary founders and executives, providing them with resources and services to launch and scale innovative brands. Redbud Brands emphasizes 'better-for-you' products and offers access to capital, a shared services platform featuring a network of experienced executives, and strategic relationships with retailers, distributors, and suppliers. This comprehensive support system is designed to empower entrepreneurs to build transformative and sustainable businesses that aim to make a positive impact on society.

Credo AI is focused on enabling enterprises to responsibly develop, adopt, and utilize artificial intelligence at scale. The company offers an AI governance platform that automates oversight and risk management, ensuring compliance with emerging global standards such as the EU AI Act and NIST. Founded in 2020, Credo AI's platform supports organizations in measuring, monitoring, and managing risks associated with AI, which helps build customer trust and unlock sales opportunities. By prioritizing human control over AI technologies, Credo AI aims to enhance both business outcomes and societal benefits. The company has received recognition in the industry, including listings in CBInsights AI 100 and accolades from the World Economic Forum and Fast Company.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Red Sift is a cybersecurity company that specializes in enhancing organizations' digital resilience through its comprehensive Digital Resilience Platform. This platform is designed to address vulnerabilities across an organization's entire digital footprint, offering advanced discovery and monitoring capabilities for email, domains, brand protection, and network perimeter security. By leveraging machine learning, Red Sift provides users with tools to analyze and synthesize data, enabling proactive threat detection and effective remediation strategies against phishing attacks while ensuring compliance with web security protocols. With a diverse client base that includes notable companies such as Domino’s, ZoomInfo, and various global law firms, Red Sift operates globally with offices in North America, Australia, Spain, and the UK, and collaborates with trusted partners like Entrust and Microsoft to enhance its offerings.

Speech Graphics Ltd, founded in 2010 and based in Edinburgh, United Kingdom, specializes in procedural facial animation solutions for the entertainment industry. The company offers SGX, a software that transforms audio files and transcripts into high-quality facial animations without the need for motion capture. Its technology has been utilized in various productions, including AAA video games and music videos, and serves applications in communication and training. The firm emerged from the University of Edinburgh's School of Informatics and has collaborated with notable clients such as Warner Brothers and Def Jam Recordings. Speech Graphics has garnered several awards for its innovative technology, including the John Logie Baird Award, and has received development grants from organizations like Scottish Enterprise.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

Codoxo, previously known as Fraudscope, specializes in developing an AI-assisted platform aimed at enhancing the efficiency and affordability of healthcare systems. The company employs a patented algorithm to detect fraud, waste, and abuse within healthcare plans, enabling earlier identification of suspicious activities compared to traditional methods. This innovative approach supports investigators and analysts in deriving insights and conducting comprehensive investigations of questionable claims. By focusing on these critical areas, Codoxo helps ensure that healthcare resources are allocated effectively, ultimately contributing to improved patient care.

Nucleix Ltd. is a company that develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on identifying subtle changes in DNA methylation patterns to enhance cancer detection. The company's key products include Bladder EpiCheck, a urine test designed for monitoring bladder cancer, and Lung EpiCheck, a blood test aimed at the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix enables healthcare providers to improve treatment outcomes through more accurate cancer screening and monitoring. The company has established distribution partnerships in several countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Upgrade Inc., established in 2016 and headquartered in San Francisco with additional offices across North America, operates an online lending platform that combines access to personal loans and the Upgrade Card with free credit education tools and monitoring services. The company aims to provide affordable and responsible credit solutions to mainstream consumers, offering products such as personal loans and a unique credit card designed for use at retail locations nationwide. Additionally, Upgrade offers mobile banking products and educational resources to help consumers understand and manage their finances effectively.

Ankyra is a biotechnology company focused on developing anchored immunotherapy for cancer treatment. The company addresses the limitations of traditional cytokine therapies, which are often restricted due to widespread immune activation and associated toxicity. Ankyra's innovative approach involves the use of its Anchored Immunotherapy Platform to create ANK-101, a stable complex of a modified IL-12 cytokine and aluminum hydroxide, an FDA-approved adjuvant. This combination allows for targeted intratumoral delivery, enhancing the localized retention and activity of IL-12 while reducing systemic side effects. By optimizing the therapeutic potential of anchored immunotherapy, Ankyra aims to improve treatment outcomes for cancer patients, offering a safer and more effective alternative to conventional therapies.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

SafeBreach Inc. is a cybersecurity company that specializes in breach and attack simulation (BAS). Founded in 2014 and headquartered in Sunnyvale, California, with an additional location in Tel Aviv, Israel, SafeBreach offers a platform that enables organizations to proactively assess their security posture. The platform utilizes a comprehensive Hacker's Playbook, which includes real-world breach methods, to simulate potential attacks across various network segments, cloud environments, and endpoints. By mimicking the tactics of virtual hackers, SafeBreach helps businesses identify vulnerabilities and improve their security controls before actual breaches occur. The platform integrates seamlessly with security information and event management systems, ticketing systems, and automation vendors, allowing for enhanced incident response and remediation. Funded by notable investors, SafeBreach continues to innovate in the field of cybersecurity, providing vital insights to strengthen enterprise defenses against evolving threats.

SafeRide Health is a healthcare technology platform that focuses on enhancing medical transportation and care coordination for vulnerable populations. The company provides a comprehensive platform that empowers health plans to manage their members effectively, ensuring greater intelligence and control over services. By utilizing advanced technology and artificial intelligence, SafeRide Health facilitates end-to-end data transparency, which in turn improves patient experiences and outcomes. The platform aims to transform the patient journey, enhance population health, and reduce overall healthcare costs through its innovative solutions, including patented fleet management capabilities tailored to the healthcare industry.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018, the company operates from locations in Israel, the Netherlands, and Boston. Its primary asset is Pridopidine, an oral drug candidate that has demonstrated an established safety profile and shows promise in treating various movement disorders and neurodegenerative diseases in both adults and children. Prilenia aims to enhance the functional capacity of patients, particularly those undergoing early hemodialysis, by addressing the underlying challenges posed by these conditions.

Bridgit is a Canadian technology company established in 2014, specializing in construction project management solutions. It offers two primary products: Bridgit Bench, a resource planning and workforce management tool, and Bridgit Field, an inspection, task, and communication management solution. Bridgit caters to contractors and developers, helping them streamline operations and maximize profits through a people-first approach. The company works with industry leaders such as Skanska and Balfour Beatty, and has raised over $35 million USD in equity financing from prominent investors.

Hungry is a Washington D.C.-based company that operates a food catering and delivery marketplace. Founded by Eman Pahlavani, Shy Pahlevani, and Jeff Grass, Hungry connects independent chefs with businesses seeking high-quality catered meals. The platform offers a variety of prepared meals for different occasions, allowing businesses to order office lunches from a network of local chefs with curated menus. Hungry is committed to community improvement through initiatives like the ‘Fight Against Hunger’ program, which donates one meal to those in need for every two purchased, and the ‘WeRecycle’ program, which promotes environmental waste reduction by offering biodegradable plates and cutlery. The company has operations in several major U.S. cities, including Philadelphia, Atlanta, Boston, and New York City, with plans to expand its footprint to 23 cities by the end of 2021.

Elephas is a live tumor imaging diagnostics company focused on enhancing cancer treatment through personalized therapy determination. The company leverages advancements in cancer biology, multimodal microscopy, engineering, and artificial intelligence to analyze human live tumor fragments. This innovative platform aims to improve clinical decision-making for oncologists, enabling them to tailor treatments to individual patients. Additionally, Elephas seeks to accelerate drug development processes, addressing the urgent need for effective cancer therapies in a rapidly evolving healthcare landscape.

JumpCloud, Inc. is a provider of a Directory-as-a-Service platform that simplifies identity management for organizations. Founded in 2010 and based in Louisville, Colorado, the company offers a cloud-based solution enabling secure access to systems, applications, files, and networks from any device or location. Its platform automates server management tasks, including user management, security, compliance, and configuration assessment. JumpCloud allows IT and security teams to manage user identities, devices, and permissions while applying Zero Trust principles. The company serves over 100,000 organizations globally, including more than 3,000 customers such as Cars.com, GoFundMe, and Foursquare. Originally known as SafeInstance, Inc., JumpCloud rebranded in October 2013 to reflect its focus on providing secure and frictionless access to corporate technology resources.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

PolyAI Ltd is a company that specializes in developing a conversational artificial intelligence platform aimed at enhancing human-machine voice interactions. Founded in 2017 and headquartered in London, United Kingdom, with an additional office in New York, the company focuses on creating enterprise voice assistants capable of engaging in natural conversations with customers. These assistants utilize advanced machine learning and natural language processing to understand and respond to customer inquiries, regardless of phrasing or dialect. The platform supports features such as multilingual capabilities, data acquisition, and dynamic flow design, facilitating the creation of human-like interactions and improving customer service experiences across various industries.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

#Paid is a technology company that provides a creative marketing platform designed to connect brands with social media creators for collaborative campaigns. The platform facilitates partnerships between brands and relevant creators, including artists, travelers, storytellers, and photographers, to enhance product placement on social media. By transforming creator-generated content into paid advertisements, #Paid enables authentic and engaging collaborations that allow brands to effectively reach their target audiences through the creators' established followings.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Gusto is a software-as-a-service company specializing in Human Capital Management (HCM). It offers a comprehensive platform that simplifies payroll processing, benefits administration, and employee management for small businesses. Gusto’s services include payroll management, time and attendance tracking, and employee onboarding, all designed to meet the various HR needs of its clients. By providing an integrated system for managing employee benefits, including health, dental, and vision insurance, Gusto enables businesses to effectively support their workforce. This platform is aimed at streamlining administrative tasks, allowing small business owners to focus on their core operations while ensuring compliance with employment regulations.

Exo is a medical device startup focused on revolutionizing ultrasound technology for imaging and therapeutic applications. The company has developed a handheld ultrasound platform that integrates advanced nano-materials, innovative sensor technologies, and sophisticated signal processing with the cost advantages of semiconductor manufacturing. This approach allows Exo to provide high-quality, affordable, and user-friendly medical imaging solutions. By enabling healthcare professionals to make critical, real-time decisions, Exo aims to enhance patient outcomes significantly. The company's commitment to accessibility and ease of use in medical imaging represents a significant advancement in the field, making effective diagnostic tools available at an unprecedented price point.

Blackbuck, founded in 2015, is a leading online platform in India that connects shippers with truck operators, transforming the logistics landscape through technology. The company focuses on streamlining the trucking process by facilitating load bookings, offering price discovery, route optimization, and in-transit tracking. This comprehensive approach not only enhances operational efficiency for shippers and truckers but also supports the livelihoods of many individuals within the transportation ecosystem. Blackbuck's commitment to reliability and efficiency has positioned it as the largest trucking network in India, backed by a strong team and notable investors. The company has received multiple accolades, including the 'Young Turks Startup of the Year' award and recognition as 'Company of the Year - Logistics' in 2018. Additionally, Blackbuck's innovative business model has been featured in a Harvard Business School case study.

Wugen is focused on developing off-the-shelf cellular therapies for cancer, particularly utilizing natural killer (NK) cells and CAR-T cell therapies. The company enhances NK cells obtained from healthy donors to improve their ability to target and eliminate cancer cells. Wugen's innovative approach includes a proprietary platform that leverages advanced genomic engineering to create next-generation memory NK cell therapies. These therapies specifically aim to address various types of malignancies, including solid tumors, acute myeloid leukemia, and T-cell malignancies, thereby providing new treatment options for patients facing life-threatening cancers.

Primer Technologies, Inc., established in 2014 and headquartered in San Francisco, specializes in developing software that leverages machine learning and natural language processing to analyze vast amounts of textual data across multiple languages. Its platform automates the parsing and collation of documents, uncovering insights and generating reports comparable to those produced by human analysts. This enables governments and corporations to better understand and monitor global information, facilitating informed decision-making.

Nubank is a prominent digital bank revolutionizing finance with its customer-centric approach. It provides a variety of services, including credit cards, personal loans, and digital payments, all accessible through a simple mobile app. Known for transparency, ease of use, and low fees, Nubank aims to empower users with innovative solutions for better financial management.

Outreach Inc. is a Seattle-based company that specializes in sales engagement solutions designed to enhance revenue growth by streamlining customer interactions across various channels, including email, voice, and social media. Founded in 2011, Outreach offers a platform that utilizes machine learning to automate repetitive sales tasks, optimize communication, and provide real-time insights based on buyer sentiment. Its features include account-based sales solutions, task management, and comprehensive tracking of email and activity metrics. Outreach's clientele encompasses major companies such as Zoom, Okta, Adobe, and Microsoft, which depend on its technology to improve sales efficiency and effectiveness. The company also maintains an office in London, United Kingdom.

Klaviyo, Inc. is a technology company headquartered in Boston, Massachusetts, with an additional office in London, United Kingdom. Founded in 2012, Klaviyo specializes in providing an email marketing software platform designed to help businesses grow through effective marketing automation. Its features include a library of best practice emails, segmentation tools, analytics, customer profiles, and support for various campaigns such as abandoned cart reminders and personalized follow-ups. Klaviyo's platform integrates with customer data sources to deliver tailored messaging across email, SMS, and push notifications, enabling businesses to engage with customers at the right time. The company utilizes machine learning and artificial intelligence to enhance its services and measures performance to optimize marketing efforts. Klaviyo generates revenue through subscription sales for its software-as-a-service platform, focusing primarily on the eCommerce sector.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Boom Entertainment is a technology company that specializes in developing a sports gaming application tailored for the sports betting industry. The company focuses on creating casual gaming experiences and offers both real-money and free-to-play online sports and casino games. Collaborating with professional sports leagues, media companies, and casino operators, Boom Entertainment aims to provide innovative gaming solutions that enhance user engagement. Its applications are designed to support business-to-business providers, facilitating access to real-money games for major casino operators.

Tellius, Inc. is an AI-powered business analytics platform established in 2015 and headquartered in Reston, Virginia. The platform is designed to help enterprises accelerate data-driven insights and decision-making by integrating artificial intelligence with a search-enabled interface for ad hoc exploration. Unlike traditional business intelligence tools, Tellius employs a distributed architecture that leverages Apache Spark, enabling it to handle big data efficiently. The platform automates the interpretation and analysis of data through machine learning, identifying hidden correlations, trends, and anomalies. Users can pose questions about their business data and receive immediate insights, which are presented as suggested visualizations and predictive models, facilitating a more comprehensive understanding of their operations.

Biosplice Therapeutics is engaged in the research and development of therapeutic drugs aimed at tissue-level regeneration, with a focus on osteoarthritis and oncology. The company utilizes a platform that originated from small molecule-based modulation of the Wnt pathway, enabling the discovery of new biological targets and processes. This innovative approach allows Biosplice to develop therapeutics that address a variety of degenerative diseases, aiming to create effective treatments for conditions that currently lack adequate options. By concentrating on regenerative medicine, the company aspires to improve patient health through the advancement of new curative therapies.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

Luminoah is a medical device company focused on enhancing chronic disease care through its innovative enteral nutrition platform. The company has developed a wearable system that integrates durable medical equipment with consumable nutrition pouches. This platform allows for personalized enteral feeding, enabling doctors to remotely monitor patients and track feeding status online. By combining technology and nutrition, Luminoah aims to revolutionize the enteral feeding market and improve clinical outcomes for individuals requiring nutritional support.

WireWheel, Inc. is a software company that offers a data privacy management platform designed to assist organizations in complying with data protection regulations such as the EU GDPR, Privacy Shield, PCI DSS, and HIPAA. Founded in 2016 and based in Arlington, Virginia, WireWheel provides cloud-based solutions that help global enterprises operationalize privacy and become GDPR-ready. The platform includes features for privacy program management and subject rights request management, leveraging machine learning and data science to enhance its effectiveness. Additionally, it facilitates the automatic mapping of public cloud assets and the management of third-party relationships, helping companies navigate compliance obligations while maximizing the potential of their data assets for competitive advantage.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

Earli is a company focused on developing innovative cancer treatment devices that utilize synthetic biomarkers for early cancer detection. The company's approach involves a novel gene therapy technique known as Synthetic Biopsy, which prompts cancer cells to produce synthetic, non-human biomarkers. These biomarkers can be detected through various means, including blood, urine, or breath, allowing for timely tracking and treatment of cancer. By facilitating the early identification of cancer when it is still homogeneous, Earli aims to significantly enhance survival rates. Their technology not only aids in detection but is also applicable for therapeutic interventions, thereby personalizing treatment and improving patient outcomes.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Cytrellis Biosystems, Inc. is a clinical stage medical technology company that focuses on the design and development of devices for dermatology, scar reduction, and aesthetic medicine. Founded in 2011 and headquartered in Sherborn, Massachusetts, the company aims to address age-related skin issues by offering non-surgical solutions to remove sagging skin without causing scarring. Its innovative devices provide aesthetic practitioners with advanced tools to enhance skin appearance, thereby improving patient outcomes in the field of aesthetic medicine.

Coagulo Medical Technologies, Inc. is a Massachusetts-based company focused on developing advanced testing systems for coagulation management. The company provides a portable and connected precision-medicine platform that enables healthcare professionals to detect, identify, and quantify the effects of various anticoagulants in whole blood. By utilizing a combination of patent-pending coagulation assays, microfluidic technology, and data analytics, Coagulo's system offers actionable results, facilitating personalized diagnosis and management of coagulation-related conditions. This innovative approach aims to improve healthcare outcomes by making coagulation testing more accessible and efficient for both providers and patients.

StockX LLC is an online marketplace founded in March 2015 and headquartered in Detroit, Michigan, that facilitates the buying and selling of limited edition and high-demand sneakers. It operates a live bid/ask platform, allowing users to anonymously engage in transactions with stock market-like visibility. The marketplace offers features such as historical price and volume metrics, real-time bids and offers, and time-stamped trades, enabling users to track their sneaker collections and compare them with others on the platform. Additionally, StockX provides in-depth market analysis and news, allowing consumers to assess the value of their products and ensuring that sellers receive fair deals.

Uhnder Inc. is a technology company focused on developing innovative products for sensing, cognition, and communication within the Internet of Things (IoT) market. Founded in 2015 and headquartered in California, with engineering and operations in Austin and St. Louis, Uhnder specializes in a digital automotive radar-on-chip. This technology offers a more accurate and reliable alternative to traditional light detection and ranging (lidar) systems, which are commonly used in autonomous vehicles. The radar-on-chip enhances safety by helping to avoid collisions, providing alerts for potential issues, and enabling quick localization through electronic navigation fences. By improving feedback response and system automation, Uhnder aims to transform the autonomous vehicle landscape.

Papercup is a London-based company that specializes in automating the dubbing and translation of video content using advanced artificial intelligence. Its software employs a combination of Bayesian neural networks and speech synthesis to create synthetic voice-overs that closely resemble human speech. This technology allows video creators to produce content in their original language while enabling users to translate videos into their preferred languages. Papercup's platform streamlines the localization process, making it faster and more cost-effective compared to traditional methods. The company also incorporates a quality assurance system where professional translators review the voiceovers, ensuring high accuracy and broadcast-quality results. By enhancing video accessibility, Papercup aims to help content owners engage with a global audience more effectively.

Brightflag is a technology company that specializes in AI-powered enterprise legal management software, aimed at helping organizations manage their legal expenditures effectively. Founded in 2014, the company serves in-house legal teams and their vendors from offices in Dublin, New York, and Sydney. Brightflag's platform offers capabilities such as matter management and e-billing reporting, utilizing advanced language analysis technologies to scrutinize incoming legal invoices. This enables clients to identify opportunities for cost reductions, optimize fee arrangements, and gain comprehensive visibility into their legal spending. By processing billions of dollars in legal spend annually, Brightflag has facilitated substantial savings and streamlined administrative tasks for its users, enhancing their ability to control outside counsel costs and efficiently manage invoice approvals.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for Alzheimer's disease and related neurodegenerative conditions. The company is advancing a targeted immunotherapy drug candidate, ACU193, which is designed to selectively target amyloid-beta oligomers, believed to be a key factor in the progression of Alzheimer's disease. Acumen employs a sensitivity assay to measure soluble amyloid-beta oligomer levels in cerebrospinal fluid, which aids in the enrollment of patients for clinical trials. The Phase 1 clinical trial for ACU193 began in 2021, aiming to assess its safety, tolerability, and pharmacokinetics in patients with mild cognitive impairment and mild dementia resulting from Alzheimer's disease. Founded in 1996 and based in Livermore, California, Acumen Pharmaceuticals is committed to addressing the challenges posed by Alzheimer’s disease through innovative therapeutic approaches.

Scopely, Inc., established in 2011 and headquartered in Culver City, California, is a leading developer of mobile and tablet touchscreen-based games for casual and core gamers worldwide. The company creates, publishes, and live-operates immersive games, including popular franchises like "Star Trek™ Fleet Command," "MARVEL Strike Force," and "Stumble Guys." Scopely offers a range of services, such as game design, live operations, marketing, analytics, and advertising, empowering a consumer-directed gaming experience. With a diverse portfolio and a proprietary technology platform, Playgami™, Scopely has operations in multiple markets across Asia-Pacific, EMEA, and North America, employing a world-class team to create long-lasting game experiences.

Totient Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2016. It specializes in data analysis for drug discovery and development, focusing on identifying novel tissue-specific antigens using tertiary lymphoid structures (TLSs). The company employs advanced machine learning and immunoinformatics to extract valuable insights from large datasets, facilitating the rapid assembly of high-affinity antibody candidates. Totient's platform is versatile, enabling the development of therapeutics aimed at treating cancer, autoimmune diseases, infections, and viral conditions. By leveraging knowledge from recent research and patient-derived tissues with exceptional immune responses, Totient aims to deliver effective antibody therapeutics for a range of medical applications.

BYJU'S is a prominent global ed-tech company founded in India in 2011, dedicated to providing adaptive and engaging learning solutions to over 150 million students worldwide. The company aims to make high-quality education accessible to learners of all ages through its flagship product, BYJU's: The Learning App, and a diverse portfolio that includes brands such as Disney-BYJU's Early Learn, BYJU's FutureSchool, and WhiteHat Jr. BYJU'S employs personalized learning methodologies that cater to individual learning styles and paces, supported by a network of over 12,000 teachers. The platform utilizes original content, watch-and-learn videos, animations, and interactive simulations to create a contextual and practical learning experience. Additionally, BYJU'S has formed innovative partnerships with major companies like Disney and Google to enhance engagement. Headquartered in India, BYJU'S operates in more than 21 countries and offers programs in over 8 languages, further solidifying its position as a leader in the education technology sector.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.